Production Method 1

52286-59-6

181225-33-2

63223-86-9

80928-46-7

97744-96-2

174721-08-5

52286-74-5

948046-19-3

80952-71-2

80952-72-3

Reaction Conditions

1.1 Solvents: Ethanol ,  Water ;  4 d, 26 °C

Reference

Microbial Transformation of 20(S)-Protopanaxatriol-Type Saponins by Absidia coerulea

Chen, Guangtong; et al, Journal of Natural Products, 2007, 70(7), 1203-1206

Ginsenoside F4 Raw materials

• Ginsenoside Re

Ginsenoside F4 Preparation Products

• Ginsenoside Rh1 (63223-86-9)
• (3β,6α,12β)-3,12,20,25-Tetrahydroxydammaran-6-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside (80928-46-7)
• sanchinoside-B1 (97744-96-2)
• Ginsenoside Rh4 (174721-08-5)
• Ginsenoside Rg2 (52286-74-5)
• (3beta,6alpha,12beta,20E)-3,12,25-Trihydroxydammar-20(22)-en-6-yl 2-O-6-deoxy-alpha-L-mannopyranosyl-beta-D-glucopyranoside (948046-19-3)
• (20R)-Ginsenoside Rh1 (80952-71-2)
• 20(R)-Ginsenoside Rg2 (80952-72-3)
• Ginsenoside F4 (181225-33-2)

• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 5. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene saponins
• Triterpenoids

Ginsenoside F4: A Comprehensive Overview

Ginsenoside F4, also known by its CAS number 181225-33-2, is a bioactive compound belonging to the class of ginsenosides, which are triterpenoid saponins found in the roots and rhizomes of plants in the genus *Panax* (ginseng). As a member of this diverse group, Ginsenoside F4 has garnered significant attention due to its potential pharmacological activities and therapeutic applications. This article delves into the latest research findings on Ginsenoside F4, exploring its structural characteristics, biological functions, and clinical implications.

Structural Characteristics of Ginsenoside F4

Ginsenoside F4 is a glycosylated triterpenoid with a unique molecular structure. Its core skeleton consists of a dammarane-type triterpene, which is modified by the attachment of specific sugar moieties. The glycosylation pattern of Ginsenoside F4 plays a crucial role in determining its bioavailability and pharmacokinetics. Recent studies have employed advanced analytical techniques, such as high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy, to elucidate the precise structure of this compound. These findings have provided valuable insights into the stereochemistry and functional groups present in Ginsenoside F4, paving the way for further research into its biological properties.

Biological Activities and Pharmacological Effects

The biological activities of Ginsenoside F4 have been extensively studied in recent years. One of the most notable findings is its potent anti-inflammatory properties. Research conducted in 2023 demonstrated that Ginsenoside F4 significantly inhibits the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), in both in vitro and in vivo models. This suggests that Ginsenoside F4 could be a promising candidate for the development of anti-inflammatory therapies.

In addition to its anti-inflammatory effects, Ginsenoside F4 has also been shown to possess strong antioxidant properties. A study published in 2023 revealed that this compound effectively scavenges free radicals and reduces oxidative stress in human cells. These findings highlight its potential as a natural antioxidant agent, which could be utilized in the prevention and treatment of oxidative stress-related diseases, such as cardiovascular disorders and neurodegenerative conditions.

Another area of interest is the neuroprotective effects of Ginsenoside F4. Preclinical studies have demonstrated that this compound protects against neuronal damage caused by oxidative stress and inflammation. Furthermore, it has been shown to enhance cognitive function in animal models of Alzheimer's disease by promoting neurogenesis and synaptic plasticity. These results underscore the potential of Ginsenoside F4 as a therapeutic agent for neurodegenerative disorders.

Clinical Applications and Future Directions

The growing body of evidence supporting the therapeutic potential of Ginsenoside F4 has sparked interest in its clinical applications. Currently, several preclinical studies are underway to evaluate its efficacy in treating chronic inflammation, oxidative stress-related diseases, and neurodegenerative conditions. Moreover, researchers are exploring the possibility of using Ginsenoside F4 as an adjuvant therapy in cancer treatment due to its reported anti-tumor properties.

One promising avenue for future research is the investigation of Ginsenoside F4's bioavailability and metabolism in humans. Understanding how this compound is absorbed, distributed, metabolized, and excreted is crucial for optimizing its therapeutic potential. Advances in pharmacokinetic modeling and metabolomics are expected to provide valuable insights into these processes.

In conclusion, Ginsenoside F4, with its CAS number 181225-33-2, represents a valuable compound with diverse biological activities and therapeutic applications. The latest research findings underscore its potential as an anti-inflammatory, antioxidant, and neuroprotective agent. As further studies continue to unravel its mechanisms of action and clinical efficacy, Ginsenoside F4 holds great promise for advancing modern medicine.

• 142735-55-5(b-D-Galactopyranoside, (1b,3b,16b,22S)-1-(b-D-glucopyranosyloxy)-3,22-dihydroxycholest-5-en-16-yl(9CI))
• 147419-93-0(Ginsenoside Rg6)
• 100187-68-6(b-D-Glucopyranoside, (3b,6b)-5,6,16-trihydroxygrayanotox-9-en-3-yl (9CI))
• 142735-53-3(b-D-Galactopyranoside, (1b,3b,16b,22S)-1,3,22-trihydroxycholest-5-en-16-yl (9CI))
• 105558-26-7(Ginsenoside Rh3)
• 143815-99-0(b-D-Glucopyranoside, (3b,22E,24S)-stigmasta-5,22,25-trien-3-yl(9CI))
• 139953-19-8(Cholest-5-ene-3,16,22-triol; (3β,16β,22S)-form, 3-O-β-D-Glucopyranoside, 16-O-[α-L-rhamnopyranosyl-(1→3)-β-D-galactopyranoside])
• 126223-28-7(Ginsenoside Rg4)
• 186763-78-0(Ginsenoside Rg5)
• 26048-07-7(β-D-Galactopyranoside, (3β,20S)-3-hydroxypregn-5-en-20-yl O-β-D-glucopyranosyl-(1→6)-O-β-D-glucopyranosyl-(1→2)-6-deoxy-3-O-methyl-)